Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by approximately 20% at 1 year in patients with overweight or obesity, according to a presentation.Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular